Renal involvement in children with COVID-19 infection

Hossein Emad Momtaz*ID

Division of Pediatric Nephrology, Hamadan University of medical sciences, Hamadan, Iran

ABSTRACT

Perhaps when China reported its first cases of the novel coronavirus in December 2019, few would predict that it would overwhelm the majority of the global community. The first reports conveyed that the rate of infection and death from this virus among children is rare. However, evidence showed that there is no particular age range for the disease and children, infants and even neonates may be infected. Although COVID-19 primarily targets the host’s respiratory system, complications in other organs such as heart, kidney and liver have been observed as well. This mini-review attempts to consider the publications focused on the COVID-19 infection among children with emphasis on renal involvement and the treatment approach of this complication.

Introduction

Coronavirus belongs to the RNA virus family which is able to infect both humans and animals. Other strains of this virus were known to be responsible for human upper respiratory infections, which present themselves with symptoms similar to the common cold such as fever, runny nose and sore throat, self-resolving in a few days without creating serious complications or requiring significant treatment. However, in the past 18 years ago, two strains of the coronavirus family began to exhibit different behavior.

First, in 2003, cases of the severe acute respiratory syndrome (SARS) were reported and then in 2012, the Middle East respiratory syndrome (MERS) involved various countries, both caused by strains of coronavirus. The novel coronavirus or COVID-19, however, reported first in the Chinese city of Wuhan on December 31, 2019 has burdened the majority of the global community and has left tens of thousands of people dead.

SARS, which first cases of this disease were reported in November 2002 in China, infected 8098 people from 29 countries resulting in 774 deaths. SARS was characterized to infect fewer children than adults and showed milder symptoms as well as quicker recovery in pediatric age group. In a study on patients clinically suspected to SARS, only 135 cases aged below 18 years were reported, among whom only 80 cases were confirmed by laboratory tests while there was no mortality among them.

First cases of MERS were reported in Saudi Arabia in September 2012 and infected 701 people by June 2014, while 249 of them died. Like SARS, MERS mostly infected adults and only 14 of the patients (2%) were children while 2 of them eventually lost their lives.

As the recent coronavirus infection (COVID-19) caused an unprecedented pandemic in the world, healthcare professionals suggested that the probability of infection and mortality among children will be extremely low based on epidemiological estimates derived from experiences with MERS and SARS infections. Yet, more recent reports began to show different patterns of involvement in

*Corresponding author: Hossein Emad Momtaz, Email: hemmtz@yahoo.com, momtaz@umsha.ac.ir
children like renal disturbance.

Methods and Materials
In order to undertake this review, the keywords “COVID-19”, “Children”, “Kidney”, “Proteinuria”, “Hematuria” and “acute kidney injury” were searched in PubMed, EMBASE, Cochrane and Scopus databases, implementing the most relevant publications.

Results
According to an article published in March 2020 by Qiu et al, in 36 children under the age of 16 years with confirmed COVID-19 infection, the most common route of transmission in 89% of children was close contact with infected family members. The average age of infected children was 3.8 years old. Around 47% of patients had mild symptoms while 28% were asymptomatic and 19% showed acute respiratory symptoms.

The most common symptoms were fever and dry cough and the most common laboratory findings were an increase in procalcitonin, a high CPK-MB and lymphopenia. None of the patients showed an increase in plasma urea and creatinine since all were successfully treated with medical treatment (1).

In a study by Sun et al in March 2020, findings of 8 children from 2 months to 15 years old infected by COVID-19 were analyzed. The most common symptoms included tachypnea, fever and coughs respectively. Chest X-ray in 7 patients showed multiple patchy involvements with ground glass appearance in 6 patients. Leukocyte counts in 7 patients were high and in 6 patients an increase of C-reactive protein (CRP), lactate dehydrogenase (LDH) and procalcitonin was detected. Two patients required ventilators. Only two patients experienced an increase in serum creatinine but none required dialysis. Finally, five patients recovered and were discharged while three remained in pediatric intensive care unit (PICU) (2).

In a report by the Korean center for infectious disease research (KCDC), of 4212 confirmed COVID-19 cases, 201 were children, 32 of which were below 9 years of age and the other 169 were between 10 to 19 years old. The youngest patient was 45 days old and the majority of children experienced mild symptoms with no deaths reported (3).

Similarly, Zheng et al studied 25 COVID-19 infected children. The average age was three years old since 40% was below 3 years. The most common symptoms were fever and dry coughs. Chest X-ray was normal in 8 patients (33.3%), however unilateral lung involvement in 5 patients and bilateral involvement in 11 patients was seen. Two patients with severe infection required ventilators and the same patients experienced an increase in serum creatinine, while one of them was treated with continuous venovenous hemodiafiltration (CVVHDF) and plasmapheresis resulting in significant improvement.

No deaths were reported among the children (4).

Ji et al reported two children with 9 and 15 years of age who were positive for COVID-19. They had the history of the COVID-19 infection in close family contacts. Both patients showed mild respiratory and gastrointestinal symptoms, and their chest X-ray results were normal with no involvement in other organs. They completely recovered through supportive treatments (5). Additionally, Su et al compared 5 children infected with COVID-19 to 14 infected adults from their family and concluded that children commonly contract the infection from family members. Although the symptoms are milder and prognosis is better, fecal excretion of virus continues longer than adults. Due to mild symptoms or asymptomatic cases, diagnosis proves to be more difficult. In their report, renal function of all the children was normal and no deaths were reported (6).

Accordingly, Dong et al in a study reported that among 2143 children presumed to be infected with COVID-19, 731 were tested positive while 1412 were suspicious of infection. Most of them showed mild symptoms and only 5.9% suffered from the severe form of the illness. This is significantly lower than the rate of severe cases in adults that were reported to be 18.5%. Only one death, in a 14-year-old boy, was reported in this study (7).

In a recent study among 72314 cases of COVID-19 in China, Lu et al detected only 1% of COVID-19 in children below 10 years old. The average age of the infected children was 6.7 years since 15.8% showed no clinical findings or imaging findings in favor of infection. In 7% of infected children; despite radiological findings, no clinical symptoms were observed. Among these patients only 3 required PICU, while all of them with associated conditions such as hydronephrosis, leukemia and intussusceptions. Only one death, in a 10-month-old infant with intussusception and multiple organ failure, was reported (8).

Likewise, the recent study by Naicker et al in March 2020 suggested that COVID-19 infection can be seen in all ages including children, with children experiencing rhinorrhea and productive cough more than adults. However, severe symptoms were not common among children (9).

Kidney involvement in COVID-19
While in previous infections such as SARS and MERS, acute kidney injury (AKI) was reported to be up to 15% with a mortality rate of approximately 60% to 90%, however initial reports of COVID-19 suggest a lower rate in adults (3% to 9%).

In the study by Wang et al, out of 138 adults infected with COVID-19, five (6.3%) suffered from AKI. There was no significant difference of AKI prevalence in patients admitted in ICU and the patients admitted in other wards (10).

Moreover, Li et al observed that in infected patients by
COVID-19, urinalysis showed proteinuria and hematuria. This finding was observed in both severe and mild cases without significant difference. Additionally, 31% of the patients had raised BUN and 22% showed an increase in serum creatinine. Among these patients 7 patients (4%) required continuous renal replacement therapy (CRRT), all of whom suffered from the severe form of the infection (11). More recently, in a study by Cheng et al on 710 adults infected with COVID-19, 44% had proteinuria and hematuria. Additionally, 15.5% of the patients had raised serum creatinine and in 16.1% an increase in BUN was detected (12).

**Mechanism of kidney injury**

Yet, it is possible that the cause of renal impairment lays in the direct invasion of virus to the renal tubular cells or due to cytokine storm. Angiotensin-converting enzyme (ACE) and dipeptidyl peptidase-4 (DPP4) which reside on renal tubular cells were previously known as receptors for SARS and “human coronavirus Erasmus Medical Center” (hCOV-EMC) viruses since in both of these infections the RNA of virus was extracted from renal tissues (13,14). Recently COVID-19 was extracted from the patients’ urine which may be an indicator for kidney involvement (15).

More recently, Pan et al demonstrated that the COVID-19 virus can cause direct injury to podocytes and proximal tubular cells through attaching to ACE2 receptors and cellular transmembrane serine protease enzyme activity which may explain proteinuria in COVID-19 patients. They also proposed that the simultaneous expression of ACE2 receptor genes and cellular transmembrane serine protease in kidney cells are not less than in other organs, therefore kidney is also a target organ for the COVID-19 virus (16).

**Treatment**

Although no definitive treatment has been found at the time of this writing, several medications such as chloroquine phosphate, lopinavir/ritonavir, remdesivir, interferon alpha, favipiravir, umifenovir and tocilizumab have been suggested as likely effective medications in controlling the disease. There are several ongoing clinical trials regarding their effectiveness and side effects (17).

Steroids seem to increase mortality rate, according to previous studies conducted on MERS and SARS patients, since administration of these group of drugs is controversial and generally not recommended (18).

Use of recovered patients’ plasma has shown promising results in primary studies but still requires further researches (19).

**COVID-19 and dialysis patients**

This infection can be a potential threat to dialysis patients. In a review, 16% of patients and 12% of staff in a dialysis ward were infected with COVID-19 since out of 7 expired patients, 6 were suffering from COVID-19 infection. Despite this risk, dialysis patients in general showed milder clinical symptoms, fewer cases of lymphopenia and lower levels of cytokines (20).

The use of CRRT in the treatment of severe COVID-19 cases has shown in some studies to be effective, however, more extensive researches are required to confirm this result (21).

**Conclusion**

Despite initial reports and background experiences of SARS and MERS cases which infection among children is rare, recent reports showed that all ages, even infants and neonates can be infected with the virus. Renal complications are reported to be limited to the severe cases in children, and are mostly presents as AKI in the context of multi-organ failure caused by direct virus invasion or acute inflammatory response. In a limited number of studies conducted among adults, proteinuria and hematuria were observed in patients. However, studies on children have not yet been conducted. More studies of renal complications in children with COVID-19 infection are recommended in initial stages of this disease.

**Author’s contribution**

HEM searched the data, prepared, edited and finalized the paper. The author read and signed the final manuscript.

**Conflicts of interest**

The author declares that he has no competing interests.

**Ethical considerations**

Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the author.

**Funding/Support**

None.

**References**


